A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors
Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety, tolerability, and preliminary antitumor activity of
CAN04 both as a monotherapy and in combination with standard of care treatment in subjects
with solid cancer tumors.
Following completion of the first part, the dose escalation cohorts, and determination of
maximum tolerated dose or recommended phase 2 dose (MTD/RP2D), safety and tolerability will
be further evaluated in an expanded cohort of subjects with pancreatic or lung cancer, as
monotherapy or in combination with the standard of care treatment, to identify the RP2D of
CAN04 in combination with standard of care. In addition, early signs of efficacy during
treatment with CAN04 will be investigated.